缺血性心肌病多支血管血运重建策略选择
该研究基于新泽西州临床注册数据,比较射血分数≤35%的多支冠状动脉病变患者接受冠状动脉旁路移植术(CABG,3673例)或经皮冠状动脉介入治疗(PCI,2315例)的长期结局。中位随访5.2年,在控制完全血运重建后,CABG与PCI的全因死亡、卒中及心衰再入院风险相似,但PCI的再次血运重建和心肌梗死风险更高。结论支持共识推荐对多支病变合并左室功能不全患者采用CABG和药物治疗。
要点
- 在完全血运重建率相似时,CABG与PCI的全因死亡、卒中和心衰再入院风险相似。
- PCI组再次血运重建风险(18% vs 14%,HR 1.62)和心肌梗死风险(10% vs 6%,HR 1.91)高于CABG组。
- PCI组完全血运重建率较低,且与PCI后更高的死亡风险相关(HR 1.35)。
核心结论
- 在实现相似完全血运重建率的情况下,缺血性心肌病患者接受CABG与PCI的全因死亡、卒中和心衰再入院风险相似,但CABG的再次血运重建风险更低。
- 这些发现支持共识推荐对多支冠状动脉病变合并左心室功能不全患者采用CABG和药物治疗。
研究设计与样本
- 研究使用新泽西州卫生部临床注册库链接行政数据库,纳入2007年至2018年间5988例射血分数≤35%且接受多支血管血运重建的缺血性心肌病患者,其中CABG 3673例(61.3%),PCI 2315例(38.6%)。
- 采用Cox比例风险模型和倾向性匹配并竞争风险分析,比较全因死亡、再次血运重建、心衰再入院、心肌梗死和卒中;中位随访时间5.2年(范围0-13年),末次随访日期为2020年12月31日。
主要发现
- 控制完全血运重建后,13年时PCI组死亡率为57%(95% CI 51-63),CABG组为60%(95% CI 53-66),HR 1.10(95% CI 0.93-1.31,P=0.28)。
- 再次血运重建风险PCI组为18%,CABG组为14%,HR 1.62(95% CI 1.17-2.25,P=0.003)。
- 心衰再入院风险PCI组和CABG组均为16%,HR 1.13(95% CI 0.84-1.51,加权P=0.10)。
- 心肌梗死风险PCI组为10%,CABG组为6%,HR 1.91(95% CI 1.18-3.09,P=0.007);卒中风险PCI组为3%,CABG组为4%,HR 0.79(95% CI 0.41-1.53,P=0.52)。
- PCI组完全血运重建率低于CABG组,且完全血运重建与PCI后死亡风险相关(HR 1.35,95% CI 1.20-1.52,P<0.001)。
关键数值与推荐
- 完全血运重建率:PCI组低于CABG组。
- 13年死亡率:PCI组57%(95% CI 51-63) vs CABG组60%(95% CI 53-66),HR 1.10(95% CI 0.93-1.31,P=0.28)。
- 再次血运重建风险:PCI组18% vs CABG组14%,HR 1.62(95% CI 1.17-2.25,P=0.003)。
- 心衰再入院风险:PCI组16% vs CABG组16%,HR 1.13(95% CI 0.84-1.51,加权P=0.10)。
- 心肌梗死风险:PCI组10% vs CABG组6%,HR 1.91(95% CI 1.18-3.09,P=0.007);卒中风险:PCI组3% vs CABG组4%,HR 0.79(95% CI 0.41-1.53,P=0.52)。
临床怎么用
- 原文结论指出,若能达到相似的完全血运重建率,CABG与PCI在全因死亡、卒中和心衰再入院方面相似,但CABG的再次血运重建风险更低。
- 原文结论认为这些发现支持共识推荐对多支冠状动脉病变合并左心室功能不全患者采用CABG和药物治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited comparative data guide the decision between coronary artery bypass grafting and percutaneous coronary intervention for multivessel revascularization in ischemic cardiomyopathy. The study objective was to compare the long-term outcomes of coronary artery bypass grafting and percutaneous coronary intervention for ischemic cardiomyopathy. METHODS: Clinical registries from the New Jersey Department of Health linked to administrative databases were used to compare all-cause mortality, repeat revascularization, heart failure readmissions, myocardial infarction, and stroke using Cox proportional hazards and propensity matching with competing risk analysis in 5988 patients with ejection fraction 35% or less who underwent coronary artery bypass grafting (3673, 61.3%) or percutaneous coronary intervention (2315, 38.6%) for multivessel coronary disease between 2007 and 2018. Median follow-up time was 5.2 years (range, 0-13 years); the last follow-up date was December 31, 2020. RESULTS: After controlling for completeness of revascularization, at 13 years, mortality was 57% (95% CI, 51-63) after percutaneous coronary intervention and 60% (95% CI, 53-66) after coronary artery bypass grafting (hazard ratio [HR], 1.10; 95% CI, 0.93-1.31; P = .28); risk of repeat revascularization was 18% for percutaneous coronary intervention versus 14% for coronary artery bypass grafting (HR, 1.62; 95% CI, 1.17-2.25; P = .003); risk of readmission for heart failure was 16% after percutaneous coronary intervention and coronary artery bypass grafting (HR, 1.13,95% CI, 0.84-1.51, weighted P = .10); risk of myocardial infarction was 10% versus 6%, respectively (HR, 1.91; 95% CI, 1.18-3.09; P = .007); and stroke risk was 3% versus 4%, respectively (HR, 0.79; 95% CI, 0.41-1.53; P = .52). Rate of complete revascularization was lower after percutaneous coronary intervention than after coronary artery bypass grafting and associated with higher mortality after percutaneous coronary intervention (HR, 1.35; 95% CI, 1.20-1.52; P < .001). CONCLUSIONS: Coronary bypass was associated with similar mortality, stroke, and heart failure readmissions, and reduced repeat revascularization compared with percutaneous coronary intervention in patients with ischemic cardiomyopathy if similar rates of complete revascularization were achieved. These findings support consensus recommendations for coronary artery bypass grafting and medical therapy in patients with multivessel coronary disease and left ventricular dysfunction.
引用
- Alzahrani AH, Itagaki S, Egorova NN, et al. Choice of revascularization strategy for ischemic cardiomyopathy due to multivessel coronary disease. J Thorac Cardiovasc Surg. 2024. PMID: 38492720. doi:10.1016/j.jtcvs.2024.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。